Creative Planning
BMRN icon

Creative Planning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Creative Planning’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$2K – 1992
2018
Q4 		$2K Buy
+200
New +$19K ﹤0.01% 1899

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's BMRN Position: Q1 2026 in Review

Creative Planning increased its BioMarin Pharmaceuticals (BMRN) stake by 67% in Q1 2026, buying an estimated $2.64M and bringing the position to 113,100 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Creative Planning first reported a position in BMRN in Q2 2013 and has held it in 51 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Creative Planning held 113,100 shares of BioMarin Pharmaceuticals worth $6.39M as of Q1 2026.
  • Creative Planning bought 45,259 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.64M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1006 holding.
  • Creative Planning first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.